ULTRA-MICRORIGIN BIOMEDICAL TECHNOLOGY CO., LTD.
Update：2026/11/10
Industries
Main Industry
Health Care
Main Product/Service
High-purity deglycosylated ginsenosides, estrogen-free placenta raw materials and skincare products, dewaxed and highly water-soluble AQC propolis, contract development of raw materials and products utilizing supercritical fluid processes, and ODM/OBM services.
The content above was translated by Ai
Founded Year
2014
Unified Business No.
24850760
Status
Closed
Number of Employees
0
Total Paid-in
Capital
- (NT$)
Location of Company
Taiwan
Website
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
The company primarily focuses on the research and development of novel anti-cancer botanical drugs, supplemented by the development of raw materials for health supplements and the design of customized health supplements. The company's primary technology platforms include extraction, separation, and purification processes utilizing supercritical fluid technology, as well as natural product analysis and (cancer) cell research platforms. In 2020, the company merged with Gwo Xi Stem Cell.
The content above was translated by Ai
